Synopsis
Synopsis
0
KDMF
0
VMF
0
FDA Orange Book
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anaspaz
2. Atropine Sulfate, 3(s)-endo-isomer
3. Atropine, 3(s)-endo-isomer
4. Cytospaz
5. Hyoscyamine
6. Hyoscyamine Hydrobromide
7. Hyoscyamine Hydrochloride
8. Hyoscyamine Sulfate
9. Hyoscyamine Sulfate Anhydrous
1. Hyoscyamine Sulfate
2. Schembl34273
3. Chembl1697729
Molecular Weight | 387.4 g/mol |
---|---|
Molecular Formula | C17H25NO7S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 387.13517331 g/mol |
Monoisotopic Mass | 387.13517331 g/mol |
Topological Polar Surface Area | 133 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 434 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Mydriatics
Agents that dilate the pupil. They may be either sympathomimetics or parasympatholytics. (See all compounds classified as Mydriatics.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
Japanese Pharmacopoeia Scopolia Extract
Registration Number : 217MF11030
Registrant's Address : 2-10-50 Mukaimachi, Furukawa-cho, Hida-shi, Gifu Prefecture
Initial Date of Registration : 2005-12-02
Latest Date of Registration : 2010-04-01
Alchem offers Phytochemical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.
Hyoscyamine Sulphate EP/USP & Hyoscyamine Hydrobromide USP
Date of Issue : 2022-05-27
Valid Till : 2025-05-26
Written Confirmation Number : WC-0006
Address of the Firm : 25/2, Main Mathura Road, Village Kalli, Ballabgarh, Faridabad-121 004, Haryana, ...
Date of Issue : 2024-05-20
Valid Till : 2027-01-08
Written Confirmation Number : WC-0300
Address of the Firm : Plot no.1710 & A1-2208 GIDC Estate 3rd Phase, Vapi Gujarat 396195
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
97
PharmaCompass offers a list of Hyoscyamine Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hyoscyamine Sulfate manufacturer or Hyoscyamine Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hyoscyamine Sulfate manufacturer or Hyoscyamine Sulfate supplier.
PharmaCompass also assists you with knowing the Hyoscyamine Sulfate API Price utilized in the formulation of products. Hyoscyamine Sulfate API Price is not always fixed or binding as the Hyoscyamine Sulfate Price is obtained through a variety of data sources. The Hyoscyamine Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Levsin sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levsin sulfate, including repackagers and relabelers. The FDA regulates Levsin sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levsin sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Levsin sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Levsin sulfate supplier is an individual or a company that provides Levsin sulfate active pharmaceutical ingredient (API) or Levsin sulfate finished formulations upon request. The Levsin sulfate suppliers may include Levsin sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Levsin sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Levsin sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Levsin sulfate active pharmaceutical ingredient (API) in detail. Different forms of Levsin sulfate DMFs exist exist since differing nations have different regulations, such as Levsin sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Levsin sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Levsin sulfate USDMF includes data on Levsin sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Levsin sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Levsin sulfate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Levsin sulfate Drug Master File in Japan (Levsin sulfate JDMF) empowers Levsin sulfate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Levsin sulfate JDMF during the approval evaluation for pharmaceutical products. At the time of Levsin sulfate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Levsin sulfate suppliers with JDMF on PharmaCompass.
A Levsin sulfate CEP of the European Pharmacopoeia monograph is often referred to as a Levsin sulfate Certificate of Suitability (COS). The purpose of a Levsin sulfate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Levsin sulfate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Levsin sulfate to their clients by showing that a Levsin sulfate CEP has been issued for it. The manufacturer submits a Levsin sulfate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Levsin sulfate CEP holder for the record. Additionally, the data presented in the Levsin sulfate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Levsin sulfate DMF.
A Levsin sulfate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Levsin sulfate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Levsin sulfate suppliers with CEP (COS) on PharmaCompass.
A Levsin sulfate written confirmation (Levsin sulfate WC) is an official document issued by a regulatory agency to a Levsin sulfate manufacturer, verifying that the manufacturing facility of a Levsin sulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Levsin sulfate APIs or Levsin sulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Levsin sulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Levsin sulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Levsin sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Levsin sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Levsin sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Levsin sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Levsin sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Levsin sulfate suppliers with NDC on PharmaCompass.
Levsin sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levsin sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levsin sulfate GMP manufacturer or Levsin sulfate GMP API supplier for your needs.
A Levsin sulfate CoA (Certificate of Analysis) is a formal document that attests to Levsin sulfate's compliance with Levsin sulfate specifications and serves as a tool for batch-level quality control.
Levsin sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Levsin sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levsin sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Levsin sulfate EP), Levsin sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levsin sulfate USP).